Table 1.
Evidence for the use of broader antifungal prophylaxis agents in childhood AML
PC indicates prospective cohort; SCT, stem cell transplantation for leukemia; and MDS, myelodysplastic syndrome.
Evidence for the use of broader antifungal prophylaxis agents in childhood AML
PC indicates prospective cohort; SCT, stem cell transplantation for leukemia; and MDS, myelodysplastic syndrome.
